Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Nonrandomized, Open-Label, Multicenter, Phase 1 Study to Assess the Safety and Pharmacokinetics of ADASUVE® (STACCATO® Loxapine for Inhalation) at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

NCT02184767 is registered in ClinicalTrials.gov with Teva Branded Pharmaceutical Products R&D, Inc. as lead sponsor.

NCT NCT02184767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02184767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Nonrandomized, Open-Label, Multicenter, Phase 1 Study to Assess the Safety and Pharmacokinetics of ADASUVE® (STACCATO® Loxapine for Inhalation) at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2014
Completion date
May 31, 2015
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar